演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

進行・再発大腸癌後方ライン治療におけるbiweeklyTAS-102+Bevacizumab療法の治療経験

演題番号 : P19-7

[筆頭演者]
演者)前田 清:1,2 
[共同演者]
井上 透:1、日月 亜紀子:1、西居 孝文:1、永原 央:2、渋谷 雅常:2、福岡 達成:2、久保 尚士:1、玉森 豊:1、櫻井 克宣:1、金沢 景繁:1、登 千穂子:1、後藤 航:1、清水 貞利:1、大平 雅一:2

1:大阪市立総合医療センター・消化器外科、2:大阪市立大学・消化器外科

 

[Introduction] In patients with unresectable metastatic colorectal cancer in refractory setting, TAS-102 plus bevacizumab has shown a significant survival benefit compared with that for TAS-102 alone. Although hematotoxicities were frequently observed in patients treated with TAS-102 plus bevacizumab, recent studies reported that biweekly administration of TAS-102 may reduce these adverse events. In this study, we investigated the efficacy and safety for biweekly TAS-102+Bevacizumab therapy.
[Patients] Eighteen patients were treated with TAS-103+Bevacizumab therapy. Six out of 18patients, TAs-102were administered biweekly.
[Results] Although neither complete response nor partial response were not observed, 13 (72.2%) out of 18 patients were diagnosed as stable disease (SD). Four (67.7%) out of 6 patients who were treated with biweekly TAS-102+Bevacizumab therapy were diagnosed as SD. According to Progression-free survival (PFS), median PFS was 3.9months (1.6-11.0) in all 18 patients and 4.3months (2.3-6.1) in 6patients with biweekly TAS-102 plus bevacizumab, respectively. According to adverse events, G3 neutropenia was observed in 3 patients, however none was observed in patients with biweekly TAS-102 plus Bevacizumab therapy.
[Conclusion] Biweekly TAS-102+Bevacizumab therapy may reduce adverse event, such as hematotoxicities without decrease for efficacy and is thought to be useful treatment option for patients with metastatic colorectal cancer in a refractory setting.

キーワード

臓器別:大腸・小腸

手法別:化学療法

前へ戻る